Top in endocrinology: New tirzepatide data, plus other highlights from ObesityWeek

After participating in a 12-week lifestyle intervention followed by 72 weeks of tirzepatide, adults with obesity lost a mean of 24.3% of their body weight, researchers reported.

Additionally, almost 45% of adults achieved weight loss of 20% or greater with tirzepatide, according to data from the SURMOUNT-3 trial.

It was the top story in endocrinology last week.

The second top story was about an investigational GLP-1/GIP dual agonist that induced up to 7.8% weight loss at 28 days in a phase 1 study.

Read these and more top stories in endocrinology below:

SURMOUNT-3: ‘Substantial’ weight loss with tirzepatide after lifestyle intervention

Adults with obesity who received tirzepatide for 72 weeks following a 12-week intensive lifestyle intervention achieved a total mean weight loss greater than 24%, according to data from the SURMOUNT-3 trial. Read more.

Dual GLP-1/GIP agonist shows promising impact on liver fat, lipids on top of weight loss

New data presented at ObesityWeek demonstrate an encouraging early profile of an investigational dual GLP-1/GIP receptor agonist in healthy adults, according to a speaker at ObesityWeek. Read more.

Children who switch between foods more frequently during meals gain more fat mass

Children who switch between foods more frequently while eating may be more likely to gain weight, according to a speaker at ObesityWeek. Read more.

Weight loss varies with investigational triple agonist for adults with obesity

Weight loss with the triple-hormone agonist retatrutide varies by sex, age and baseline BMI, according to a speaker. Read more.

Certain antidepressants may cause more weight gain over 2 years

Initiation and continued use of certain antidepressants may cause more weight gain over 2 years, according to research presented at ObesityWeek. Read more.